(NATR) Natures Sunshine Products - Ratings and Ratios
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US6390271012
Supplements, Herbal Remedies, Personal Care, Weight Management
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 46.2% |
| Value at Risk 5%th | 61.7% |
| Relative Tail Risk | -18.71% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.86 |
| Alpha | 32.84 |
| CAGR/Max DD | 0.91 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.355 |
| Beta | 0.257 |
| Beta Downside | 0.177 |
| Drawdowns 3y | |
|---|---|
| Max DD | 45.66% |
| Mean DD | 17.24% |
| Median DD | 17.87% |
Description: NATR Natures Sunshine Products October 28, 2025
Natures Sunshine Products, Inc. (NASDAQ: NATR) is a U.S.–based natural health and wellness company that manufactures and distributes nutritional supplements and personal-care items across North America, Europe, Asia, and Latin America. Its portfolio spans blood-sugar, bone, cellular, cognitive, joint, mood, sexual health, sleep, sports-energy, vision, immune, cardiovascular, and digestive supplements, as well as aloe-based lotions, herbal shampoos, toothpaste, and weight-management products, sold under the Nature’s Sunshine and Synergy WorldWide brands through a direct-to-consumer model and a network of independent consultants.
Key recent metrics (FY 2023): total net revenue ≈ $226 million, gross margin ≈ 38%, and cash & cash equivalents ≈ $30 million, with a net loss of about $10 million reflecting ongoing restructuring costs. The global natural-supplement market is projected to expand at a ~6% CAGR through 2028, driven by an aging population and rising consumer preference for “clean-label” products-both tailwinds that could support NATR’s top-line growth if it can capture share in the e-commerce channel, which now accounts for roughly 25% of its sales.
For a deeper, data-driven look at NATR’s valuation metrics and peer comparisons, you might find the analysis on ValueRay worth a quick glance.
Piotroski VR‑10 (Strict, 0-10) 8.5
| Net Income (15.1m TTM) > 0 and > 6% of Revenue (6% = 28.5m TTM) |
| FCFTA 0.12 (>2.0%) and ΔFCFTA 6.64pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 21.59% (prev 21.65%; Δ -0.07pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.14 (>3.0%) and CFO 37.6m > Net Income 15.1m (YES >=105%, WARN >=100%) |
| Net Debt (-81.3m) to EBITDA (42.0m) ratio: -1.94 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.22 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (18.0m) change vs 12m ago -4.53% (target <= -2.0% for YES) |
| Gross Margin 72.28% (prev 71.43%; Δ 0.85pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 186.0% (prev 181.4%; Δ 4.62pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 385.9 (EBITDA TTM 42.0m / Interest Expense TTM 71.0k) >= 6 (WARN >= 3) |
Altman Z'' 5.87
| (A) 0.39 = (Total Current Assets 186.1m - Total Current Liabilities 83.6m) / Total Assets 264.8m |
| (B) 0.27 = Retained Earnings (Balance) 72.8m / Total Assets 264.8m |
| (C) 0.11 = EBIT TTM 27.4m / Avg Total Assets 255.1m |
| (D) 1.64 = Book Value of Equity 160.5m / Total Liabilities 98.1m |
| Total Rating: 5.87 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 74.67
| 1. Piotroski 8.50pt |
| 2. FCF Yield 10.88% |
| 3. FCF Margin 6.59% |
| 4. Debt/Equity 0.09 |
| 5. Debt/Ebitda -1.94 |
| 6. ROIC - WACC (= 3.18)% |
| 7. RoE 9.51% |
| 8. Rev. Trend 56.21% |
| 9. EPS Trend 10.99% |
What is the price of NATR shares?
As of December 14, 2025, the stock is trading at USD 22.74 with a total of 158,888 shares traded.
Over the past week, the price has changed by +3.93%, over one month by +9.91%, over three months by +34.08% and over the past year by +43.74%.
Over the past week, the price has changed by +3.93%, over one month by +9.91%, over three months by +34.08% and over the past year by +43.74%.
Is NATR a buy, sell or hold?
Natures Sunshine Products has received a consensus analysts rating of 5.00.
Therefore, it is recommended to buy NATR.
- Strong Buy: 2
- Buy: 0
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the NATR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 22.5 | -1.1% |
| Analysts Target Price | 22.5 | -1.1% |
| ValueRay Target Price | 22.8 | 0.3% |
NATR Fundamental Data Overview December 10, 2025
Market Cap USD = 368.8m (368.8m USD * 1.0 USD.USD)
P/E Trailing = 25.8148
P/E Forward = 16.0256
P/S = 0.7771
P/B = 2.385
Beta = 0.962
Revenue TTM = 474.5m USD
EBIT TTM = 27.4m USD
EBITDA TTM = 42.0m USD
Long Term Debt = 14.3m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 4.60m USD (from shortTermDebt, last quarter)
Debt = 14.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -81.3m USD (from netDebt column, last quarter)
Enterprise Value = 287.5m USD (368.8m + Debt 14.3m - CCE 95.6m)
Interest Coverage Ratio = 385.9 (Ebit TTM 27.4m / Interest Expense TTM 71.0k)
FCF Yield = 10.88% (FCF TTM 31.3m / Enterprise Value 287.5m)
FCF Margin = 6.59% (FCF TTM 31.3m / Revenue TTM 474.5m)
Net Margin = 3.18% (Net Income TTM 15.1m / Revenue TTM 474.5m)
Gross Margin = 72.28% ((Revenue TTM 474.5m - Cost of Revenue TTM 131.5m) / Revenue TTM)
Gross Margin QoQ = 73.28% (prev 71.72%)
Tobins Q-Ratio = 1.09 (Enterprise Value 287.5m / Total Assets 264.8m)
Interest Expense / Debt = 0.18% (Interest Expense 26.0k / Debt 14.3m)
Taxrate = 42.77% (4.14m / 9.67m)
NOPAT = 15.7m (EBIT 27.4m * (1 - 42.77%))
Current Ratio = 2.22 (Total Current Assets 186.1m / Total Current Liabilities 83.6m)
Debt / Equity = 0.09 (Debt 14.3m / totalStockholderEquity, last quarter 160.5m)
Debt / EBITDA = -1.94 (Net Debt -81.3m / EBITDA 42.0m)
Debt / FCF = -2.60 (Net Debt -81.3m / FCF TTM 31.3m)
Total Stockholder Equity = 158.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 5.70% (Net Income 15.1m / Total Assets 264.8m)
RoE = 9.51% (Net Income TTM 15.1m / Total Stockholder Equity 158.7m)
RoCE = 15.84% (EBIT 27.4m / Capital Employed (Equity 158.7m + L.T.Debt 14.3m))
RoIC = 9.88% (NOPAT 15.7m / Invested Capital 158.7m)
WACC = 6.70% (E(368.8m)/V(383.0m) * Re(6.96%) + D(14.3m)/V(383.0m) * Rd(0.18%) * (1-Tc(0.43)))
Discount Rate = 6.96% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -3.57%
[DCF Debug] Terminal Value 75.00% ; FCFE base≈23.8m ; Y1≈19.5m ; Y5≈13.9m
Fair Price DCF = 14.65 (DCF Value 256.3m / Shares Outstanding 17.5m; 5y FCF grow -21.80% → 3.0% )
EPS Correlation: 10.99 | EPS CAGR: -15.60% | SUE: 1.07 | # QB: 1
Revenue Correlation: 56.21 | Revenue CAGR: 2.28% | SUE: 2.04 | # QB: 1
EPS next Quarter (2026-03-31): EPS=0.18 | Chg30d=-0.035 | Revisions Net=-1 | Analysts=2
EPS next Year (2026-12-31): EPS=1.00 | Chg30d=+0.125 | Revisions Net=+1 | Growth EPS=-13.4% | Growth Revenue=+3.5%
P/E Trailing = 25.8148
P/E Forward = 16.0256
P/S = 0.7771
P/B = 2.385
Beta = 0.962
Revenue TTM = 474.5m USD
EBIT TTM = 27.4m USD
EBITDA TTM = 42.0m USD
Long Term Debt = 14.3m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 4.60m USD (from shortTermDebt, last quarter)
Debt = 14.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -81.3m USD (from netDebt column, last quarter)
Enterprise Value = 287.5m USD (368.8m + Debt 14.3m - CCE 95.6m)
Interest Coverage Ratio = 385.9 (Ebit TTM 27.4m / Interest Expense TTM 71.0k)
FCF Yield = 10.88% (FCF TTM 31.3m / Enterprise Value 287.5m)
FCF Margin = 6.59% (FCF TTM 31.3m / Revenue TTM 474.5m)
Net Margin = 3.18% (Net Income TTM 15.1m / Revenue TTM 474.5m)
Gross Margin = 72.28% ((Revenue TTM 474.5m - Cost of Revenue TTM 131.5m) / Revenue TTM)
Gross Margin QoQ = 73.28% (prev 71.72%)
Tobins Q-Ratio = 1.09 (Enterprise Value 287.5m / Total Assets 264.8m)
Interest Expense / Debt = 0.18% (Interest Expense 26.0k / Debt 14.3m)
Taxrate = 42.77% (4.14m / 9.67m)
NOPAT = 15.7m (EBIT 27.4m * (1 - 42.77%))
Current Ratio = 2.22 (Total Current Assets 186.1m / Total Current Liabilities 83.6m)
Debt / Equity = 0.09 (Debt 14.3m / totalStockholderEquity, last quarter 160.5m)
Debt / EBITDA = -1.94 (Net Debt -81.3m / EBITDA 42.0m)
Debt / FCF = -2.60 (Net Debt -81.3m / FCF TTM 31.3m)
Total Stockholder Equity = 158.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 5.70% (Net Income 15.1m / Total Assets 264.8m)
RoE = 9.51% (Net Income TTM 15.1m / Total Stockholder Equity 158.7m)
RoCE = 15.84% (EBIT 27.4m / Capital Employed (Equity 158.7m + L.T.Debt 14.3m))
RoIC = 9.88% (NOPAT 15.7m / Invested Capital 158.7m)
WACC = 6.70% (E(368.8m)/V(383.0m) * Re(6.96%) + D(14.3m)/V(383.0m) * Rd(0.18%) * (1-Tc(0.43)))
Discount Rate = 6.96% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -3.57%
[DCF Debug] Terminal Value 75.00% ; FCFE base≈23.8m ; Y1≈19.5m ; Y5≈13.9m
Fair Price DCF = 14.65 (DCF Value 256.3m / Shares Outstanding 17.5m; 5y FCF grow -21.80% → 3.0% )
EPS Correlation: 10.99 | EPS CAGR: -15.60% | SUE: 1.07 | # QB: 1
Revenue Correlation: 56.21 | Revenue CAGR: 2.28% | SUE: 2.04 | # QB: 1
EPS next Quarter (2026-03-31): EPS=0.18 | Chg30d=-0.035 | Revisions Net=-1 | Analysts=2
EPS next Year (2026-12-31): EPS=1.00 | Chg30d=+0.125 | Revisions Net=+1 | Growth EPS=-13.4% | Growth Revenue=+3.5%
Additional Sources for NATR Stock
News:
Wall Street Journal |
Benzinga |
Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle